Navigation Links
Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business
Date:11/8/2007

SEATTLE, Nov. 8 /PRNewswire/ -- Adaptis, a business integration provider focused exclusively on health payers, announced its majority-owned company, Tela Sourcing, Inc., has purchased HealthASPex (HAX) through an asset sale. HAX provides onshore mailroom, scanning, EDI and PPO routing services to Third Party Administrators (TPAs) and Preferred Provider Organizations (PPOs).

(Logo: http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO)

"Tela's streamlined front-end service is an integral part of our own full-spectrum business integration solution," states Jim Anderson, President and CEO of Adaptis. "Our health payer clients come to one place for all their operational functions; now we can offer them an expanded service resource for onshore front-end work, nationwide."

"We've been seeking to expand our onshore front-end services -- what better way than through a proven relationship?" asks Brij Sharma, Tela's CEO. "HealthASPex has provided Tela with onshore local mailroom and scanning functions for some time and the quality and consistency of delivery has been very impressive." Bob Carlin, President of HealthASPex will join Tela as Senior Vice President and continue to oversee all onshore operations.

Tela has grown steadily since 2003, with multiple onshore partners for mailroom and scanning operations. HAX presented an opportunity to also provide onshore front-end claims services. "We wanted to offer a one-stop onshore and offshore solution that handled mailroom, EDI, scanning and OCR -- plus all- important PPO routing," explains Sharma.

Sharma points out that the acquisition will enhance current Tela functions and adds some key strategic benefits. The company continues local partnering strategies stressing quality, economy and local presence. Also Tela gains another highly efficient OCR engine and the associated source code. The deal also allow
'/>"/>

SOURCE Adaptis
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloittes 2007 Washington State Technology Fast 50 for 4th Time in Past 6 Years
2. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
3. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
4. Adaptis Supports Local Yakima-Based YWCA and National Diabetes
5. Three New Director-Level Appointments at Adaptis
6. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
7. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
8. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
9. Food Bank For New York City Acquires FoodChange
10. Concentra Acquires Assets of Renew Health & Wellness
11. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Steaz Launches Organic Zero Calorie Sparkling Line 59893 1Steaz Launches Organic Zero Calorie Sparkling Line 59893 2Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 1Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 2Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2